Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio ...

How do you follow a genuine drug breakthrough, a cure for hepatitis C? Andrew McConaghie visits Gilead's headquarters near San Francisco to hear how the company plans to sustain its huge success.

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal ...

Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

John Martin, a chemist who became Gilead’s CEO in 1996, took some heat this year for a wonder drug that can cure hepatitis C, a disease that afflicts more than 130 million people and kills ...

Gilead Sciences specializes in developing antiviral drugs that treat HIV, hepatitis B, hepatitis C, and influenza. Recently, it has focused on expanding its oncology portfolio. The company views ...

Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence ...